GLEN Industries Ltd vs Sun Pharmaceutical Industries Ltd

A side-by-side comparison of GLEN Industries Ltd (544444) and Sun Pharmaceutical Industries Ltd (MIL) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, GLEN Industries Ltd leads 544444 vs MIL on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability40
  • Growth10
  • Size & financial health22
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

544444 takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

10.60
P/E ratio
36.90
1.34
P/B ratio
5.35
0.00%
Dividend yield
0.86%
₹6.86
EPS
₹0.70

Profitability

544444 takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.70%
Return on equity
-6.70%
14.00%
Return on capital
-1.00%
18.00%
EBITDA margin
3.50%
7.88%
Net margin
-13.10%

Growth

544444 takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

20.86%
Revenue CAGR (3Y)
-87.58%
151.98%
Profit CAGR (3Y) even

Size & financial health

Even

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹179 Cr
Market cap
₹4.42L Cr
₹203 Cr
Revenue
₹84 Cr
₹16 Cr
Net profit
₹-11 Cr
0.87
Debt / equity
0.06
GLEN Industries Ltd
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "Company might be capitalizing the interest cost"]
Sun Pharmaceutical Industries Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
GLEN Industries Ltd full analysis Sun Pharmaceutical Industries Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.